Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
In the next six months, the program aims to screen 4,000 women from underprivileged communities in and around Mathura
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
3D CMOS chip for connecting electroactive tissues and organoids to software
The citizens of Oman will soon have a coordination center that will provide end to end services for healthcare facilities of Jaslok.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
The Congress was held on June, 20-21, 2022 in Berlin, Germany
Subscribe To Our Newsletter & Stay Updated
